ArticleUpdates in surgery2026
Risk factors for complications after cytoreductive surgery (CRS) and HIPEC in 290 peritoneal malignancies of primary and secondary origins.
Article in Updates in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is effective for selected peritoneal malignancies but carries potential postoperative morbidity. Defining complication rates, severity and predictors is crucial to optimize management, patient selection, and risk stratification. A retrospective observational study was conducted including patients with primary or secondary peritoneal surface malignancies who underwent CRS-HIPEC between 2002 and 2025. Postoperative complications were graded according to CTCAE and Clavien-Dindo classifications. Early postoperative renal function was evaluated in a select cohort receiving sodium thiosulfate nephroprotection. A total of 290 patients were included (median age 60 years, PCI 5). Standard-extended peritonectomy was performed in 167 (57.6%) cases, and multivisceral resection in 27 (10.7%). Optimal debulking was achieved in 263 (90.7%). Postoperative complications occurred in 51.7%, medical and chemotherapy-related complications in 45.5% and surgical ones in 12.4% of cases. Postoperative anemia was common (32.7%), predominantly at CTCAE Grade 3. Severe complications, graded as 3-5 according to ClavienDindo score, occurred in 11.7%, mainly in elderly (20.4% vs. 9.7%, p = 0.090), with no 30-day mortality. Older age, higher comorbidity burden and splenectomy emerged as predictors of severe complications. In 22 patients receiving sodium thiosulfate, creatinine and urine output were significantly lower on postoperative day 5-7, suggesting a renal protective effect. Overall, 3-year survival was 62.2%. Anastomotic fistula (HR 2.43, p = 0.015), surgical site infection (1.81, p = 0.070), and thrombocytopenia (3.64, p < 0.001) were independent negative prognostic factors. CRS and HIPEC can be performed with acceptable morbidity and low mortality in specialized center. Further efforts to reduce complications are essential to improve postoperative outcomes and overall prognosis.
Indexed as
Identifiers
42726462What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.